Cedilla Therapeutics develops targeted small molecules that inhibit specific cancer pathways, aiming to improve treatment efficacy for various malignancies. The company focuses on addressing the limitations of current therapies by providing more precise and effective options for patients with cancer and other diseases.
Funding
$25M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer therapies often lack the precision needed to target specific cancer pathways, leading to off-target effects and limited efficacy. This imprecision can result in significant side effects and reduced quality of life for patients undergoing treatment.
Solution
Cedilla Therapeutics develops targeted small molecule inhibitors designed to selectively disrupt specific cancer pathways. By focusing on precision, Cedilla aims to create therapies that are more effective and have fewer off-target effects compared to traditional treatments. This approach seeks to improve patient outcomes by directly addressing the underlying mechanisms driving cancer growth and progression. The company's research focuses on identifying and validating novel drug targets within these critical pathways.
Target Audience
Cedilla Therapeutics' primary focus is on patients with cancer and the oncologists who treat them, as well as pharmaceutical companies seeking novel cancer therapeutics.
Features
- Development of small molecule inhibitors with high selectivity for specific cancer targets
- Focus on disrupting key signaling pathways involved in tumor growth and survival
- Preclinical validation of drug candidates in relevant cancer models
- Optimization of drug properties for improved bioavailability and efficacy